(Drug Name) (Drug Form) (Drug Strength)
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Ibandronate Sodium: Solution for injection (3mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

IBANDRONATE (i BAN droh nate) slows calcium loss from bones. It is used to treat osteoporosis in women past the age of menopause.

Similar Brand Name Drugs : Boniva: Solution for injection (3mg)
In-Depth Information
Select a Medication

Ibandronate Sodium 3mg/3mL Solution for Injection

NDC: 674570524
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Osteoporosis Prophylaxis, Osteoporosis

Sometimes used for but not FDA approved for the following conditions:
Paget's Disease, Bone Metastases, Hypercalcemia

Storage Information
Discard product if it contains particulate matter, is cloudy, or discolored
Discard unused portion. Do not store for later use.
Store at controlled room temperature (between 68 and 77 degrees F)
Ibandronate Sodium 3mg/3mL Solution for Injection

Reported Side Effects for Ibandronate Sodium 3mg/3mL Solution for Injection

Eye Inflammation Incidence:
<0.1%*
Severity: SEVERE
Onset: DELAYED
Injection Site Reaction Incidence:
<2.0%*
Severity: MILD
Onset: RAPID
Muscle Pain Incidence:
0.8-5.7%*
Severity: MILD
Onset: EARLY
Inability To Sleep Incidence:
0.8-2.6%*
Severity: MILD
Onset: EARLY
Lightheadedness Incidence:
1.0-3.7%*
Severity: MILD
Onset: EARLY
Fever Incidence:
1.1-10.0%*
Severity: MILD
Onset: EARLY
Skin Rash Incidence:
1.3-2.8%*
Severity: MILD
Onset: EARLY
Itching Incidence:
1.3-2.8%*
Severity: MILD
Onset: RAPID
Depression Incidence:
1.3-2.2%*
Severity: MODERATE
Onset: DELAYED
Skin Redness Incidence:
1.3-2.8%*
Severity: MODERATE
Onset: EARLY
Rash With Pustules Incidence:
1.3-2.8%*
Severity: MILD
Onset: EARLY
High Cholesterol Incidence:
1.5-4.8%*
Severity: MODERATE
Onset: DELAYED
Muscle Cramps Incidence:
1.8-2.0%*
Severity: MILD
Onset: DELAYED
Inflamed Stomach Incidence:
1.9-2.2%*
Severity: MODERATE
Onset: DELAYED
Upset Stomach Incidence:
2.1-5.1%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
2.4-6.8%*
Severity: MILD
Onset: EARLY
Sore Throat Incidence:
2.5-4.3%*
Severity: MILD
Onset: DELAYED
Constipation Incidence:
2.5-4.1%*
Severity: MODERATE
Onset: DELAYED
Headache Incidence:
2.6-6.5%*
Severity: MILD
Onset: EARLY
Vomiting Incidence:
2.7%*
Severity: MILD
Onset: EARLY
Balance Problems Incidence:
3.0%*
Severity: MILD
Onset: EARLY
Bladder Infection Incidence:
3.4%*
Severity: MODERATE
Onset: DELAYED
Weakness Incidence:
3.5%*
Severity: MILD
Onset: DELAYED
Joint Pain Incidence:
3.5-14.0%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
3.6-11.9%*
Severity: MILD
Onset: EARLY
Back Pain Incidence:
4.3-13.5%*
Severity: MILD
Onset: DELAYED
Infection Incidence:
4.3%*
Severity: MILD
Onset: DELAYED
Stomach Pain Incidence:
5.1-7.8%*
Severity: MILD
Onset: EARLY
High Blood Pressure Incidence:
5.3-7.3%*
Severity: MODERATE
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Ibandronate Sodium

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.